10.19
Precedente Chiudi:
$10.50
Aprire:
$10.52
Volume 24 ore:
450.62K
Relative Volume:
1.05
Capitalizzazione di mercato:
$690.35M
Reddito:
$568.09M
Utile/perdita netta:
$27.27M
Rapporto P/E:
31.11
EPS:
0.3276
Flusso di cassa netto:
$71.41M
1 W Prestazione:
+0.20%
1M Prestazione:
+12.47%
6M Prestazione:
+32.34%
1 anno Prestazione:
+52.54%
Bioventus Inc Stock (BVS) Company Profile
Nome
Bioventus Inc
Settore
Industria
Telefono
(919) 474-6700
Indirizzo
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Compare BVS vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
BVS
Bioventus Inc
|
10.19 | 711.35M | 568.09M | 27.27M | 71.41M | 0.3276 |
|
ABT
Abbott Laboratories
|
82.56 | 146.87B | 45.13B | 6.28B | 7.38B | 3.5895 |
|
SYK
Stryker Corp
|
282.58 | 109.33B | 25.27B | 3.34B | 4.57B | 8.6358 |
|
MDT
Medtronic Plc
|
74.54 | 97.77B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
53.37 | 80.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
77.17 | 46.04B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-27 | Iniziato | CJS Securities | Market Outperform |
| 2026-02-09 | Iniziato | Barrington Research | Outperform |
| 2025-07-07 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-12-07 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-09 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2022-11-22 | Downgrade | Craig Hallum | Buy → Hold |
| 2022-11-09 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-11-09 | Downgrade | JP Morgan | Overweight → Underweight |
| 2022-03-15 | Iniziato | Craig Hallum | Buy |
| 2021-11-15 | Ripresa | Morgan Stanley | Overweight |
| 2021-11-10 | Ripresa | JP Morgan | Overweight |
| 2021-07-01 | Downgrade | Goldman | Buy → Neutral |
| 2021-03-08 | Iniziato | Canaccord Genuity | Buy |
| 2021-03-08 | Iniziato | Goldman | Buy |
| 2021-03-08 | Iniziato | JP Morgan | Overweight |
| 2021-03-08 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Bioventus Inc Borsa (BVS) Ultime notizie
Bioventus (BVS) Q1 2026 Earnings Transcript - AOL.com
Wall Street analysts see a 38.97% upside in Bioventus (BVS): Can the stock really move this high? - MSN
Wall Street Analysts See a 38.97% Upside in Bioventus (BVS): Can the Stock Really Move This High? - Yahoo Finance
Bioventus Inc. (BVS) Stock Analysis: Unpacking a 38.97% Potential Upside in the Medical Devices Sector - DirectorsTalk Interviews
Bioventus (BVS) Raises FY26 Financial Guidance Following Strong Performance - GuruFocus
Bioventus (BVS) Reports Strong Q1 Revenue Growth - GuruFocus
Barrington Maintains Bioventus(BVS.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Q1 2026 Bioventus Inc Earnings Call Transcript - GuruFocus
Bioventus Inc. (NASDAQ:BVS) Q1 2026 Earnings Call Transcript - Insider Monkey
Bioventus Q1 2026 slides: earnings beat drives guidance raise By Investing.com - Investing.com Australia
Bioventus (BVS) Q1 EPS Holds Profitability But Tests Bullish Margin Narratives - Sahm
Bioventus: Q1 Earnings Snapshot - theheraldreview.com
Bioventus Earnings Call Highlights Growth, Cash Strength - TipRanks
Is Bioventus Healthcare Momentum Lifting Nasdaq ETF Attention? - Kalkine Media
Bioventus Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Bioventus outlines 2026 adjusted EPS of $0.75-$0.79 while reaffirming $600M-$610M revenue - MSN
Bioventus (BVS) surpasses Q1 earnings and revenue estimates - MSN
Bioventus Inc. Q1 2026 Financial Results: Earnings, Risk Factors, and Market Outlook - Minichart
Bioventus Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:BVS) 2026-05-06 - Seeking Alpha
Bioventus (NASDAQ:BVS) Reaches New 1-Year High on Better-Than-Expected Earnings - MarketBeat
Price-Driven Insight from (BVS) for Rule-Based Strategy - Stock Traders Daily
Bioventus Q1 Earnings Call Highlights - MarketBeat
Bioventus Q1 2026 slides: earnings beat drives guidance raise - Investing.com
Bioventus Inc. Reports Earnings Results for the First Quarter Ended March 28, 2026 - marketscreener.com
Earnings call transcript: Bioventus beats Q1 2026 forecasts, stock rises By Investing.com - Investing.com India
Earnings call transcript: Bioventus beats Q1 2026 forecasts, stock rises - Investing.com
Bioventus (BVS) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance
Bioventus : Q1'26 Earnings Call Slides - marketscreener.com
Bioventus Inc (NASDAQ:BVS) Smashes Q1 Estimates and Lifts Guidance, Shares Rally - ChartMill
Bioventus (NASDAQ:BVS) Updates FY 2026 Earnings Guidance - MarketBeat
Bioventus Q1 2026 Earnings Call Transcript - MarketBeat
BIOVENTUS ($BVS) Releases Q1 2026 Earnings - Quiver Quantitative
Bioventus reports Q1 revenue $132.1M, adjusted EPS $0.15 and raises cash-flow guidance - TradingView
Bioventus Inc. 1Q 2026: Revenue $132.09M, EPS $0.04— 10-Q Summary - TradingView
[10-Q] Bioventus Inc. Quarterly Earnings Report - Stock Titan
Bioventus (BVS) lifts 2026 EPS outlook after Q1 revenue and cash-flow gains - Stock Titan
Bioventus Reports First Quarter Financial Results - The Manila Times
Bioventus turns a profit in Q1 and pays down $22M of debt - Stock Titan
Bioventus Inc. Reaffirms Earnings Guidance for the Twelve Months Ending December 31, 2026 - marketscreener.com
Should Value Investors Buy Bioventus (BVS) Stock? - Yahoo Finance
Bioventus Inc expected to post earnings of 10 cents a shareEarnings Preview - TradingView
Bioventus Shareholder Notice - TMX Newsfile
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year? - Yahoo Finance Australia
Bioventus Inc. (NASDAQ:BVS) Given Average Rating of "Buy" by Brokerages - MarketBeat
Earnings Preview: Bioventus to Report Financial Results Pre-market on May 06 - Moomoo
Bioventus Q1 Earnings: Can It Sustain Momentum After a Strong 2025? - BriefGlance
Bioventus schedules May 6 earnings release, 8:30 a.m. call - Stock Titan
(BVS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
CCORF Maintains Bioventus(BVS.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Bioventus Deadline Alert - TMX Newsfile
BVS Earnings History & Surprises | EPS & Revenue Results | BIOVENTUS INCA (NASDAQ:BVS) - ChartMill
Bioventus Inc Azioni (BVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):